Olympus adds Hanarostent to expand its EndoTherapy portfolio

Olympus has entered into an exclusive agreement with M.I. Tech to distribute the Hanarostent. This agreement leverages company synergies in disease focus areas, while also leveraging Olympus’ robust EndoTherapy portfolio. The 510(K) cleared Hanarostent Biliary and Hanarostent Esophagus will be the first of multiple self-expanding metal stents to be rolled into the Olympus EndoTherapy portfolio for advanced procedures. Both stents provide a unique wire structure; anti-migration benefits due to a flared-end design; precise placement; and repositioning or recapture functions.

Olympus is pleased to bring these unparalleled stents, used globally, to physicians and patients in the US. The 510(K) cleared uncovered biliary stent and fully-covered oesophageal stent will bring clinical differentiation to the existing luminal patency market. Olympus will market and sell Hanarostent through its existing US distribution networks in GI. Over time, Olympus and M.I. Tech will work together to identify an appropriate pathway for other globally significant M.I. Tech products to be taken from the regulatory process through to US launch, leveraging Olympus’ established channels.